Study S001541

Impact of Semaglutide Withdrawal on Cardiometabolic Profile and Physiology of Energy Balance: a Randomized Controlled Trial Comparing Gradual Dose Reduction With Immediate Treatment Cessation.

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07294950
Acronym: REST
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: NONE
Status: RECRUITING
Enrollment: 98
Start: 2026-02-01
Primary completion: 2028-09
Lead sponsor: Mount Sinai Hospital, Canada
Conditions: Obesity (Disorder); Weight Change; Blood Pressure Monitoring; Appetite Regulation
Interventions: DRUG:Gradual dose reduction of semaglutide; DRUG:Abrupt cessation of semaglutide
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Differences in changes in body weight between each study group [32 weeks]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0008004	Impact of semaglutide withdrawal on cardiometabolic profile and physiology of energy balance: Recovery effects after semaglutide termination - The REST trial study protocol. Yevusiak T, PloS one	2026	Protocol	PMID 42507673 DOI	cites ClinicalTrials.gov:NCT07294950; registry reference DERIVED:42507673